Language
English
Publication Date
4-1-2025
Journal
Atherosclerosis
DOI
10.1016/j.atherosclerosis.2025.119114
PMID
40068508
Abstract
Familial chylomicronemia syndrome (FCS) is a rare, recessive monogenic disorder characterized by severely elevated plasma triglyceride (TG) levels due to absent or markedly impaired lipoprotein lipase activity, leading to a greatly increased risk of acute pancreatitis. Naturally occurring very low levels of apoC-III are associated with low TG levels; thus, apoC-III is a target for TG lowering, and therapies have been developed to reduce apoC-III. Strategies to inhibit hepatic apoC-III synthesis include antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs). In the last decade, technologies have been developed to enhance hepatic delivery of these potential therapeutic agents by conjugation of the ligand triantennary N-acetyl galactosamine to ASO and siRNA for receptor-mediated uptake by hepatocytes, where apoC-III is predominantly expressed. Enhanced delivery of these pharmacological agents to the target tissue has been found to support lower and/or less frequent dosing with consequent lower total systemic exposure. One antisense agent, the ASO olezarsen, is now approved by the US Food and Drug Administration (FDA) as an adjunct to diet to lower triglycerides in adults with FCS, and the other, the siRNA plozasiran, is in late-stage clinical development. Both agents have shown effectiveness in reducing both apoC-III and TG levels across several study populations. Reduced TG, lower rates of acute pancreatitis events, and similar proportions of adverse events in placebo and treated patients were recently demonstrated in placebo-controlled phase 3 trials of patients with FCS treated with olezarsen in Balance and with plozasiran in PALISADE. This review discusses causes and consequences of FCS and the rationale and progress made in developing APOC3 RNA-targeted therapeutics for the treatment of FCS.
Keywords
Humans, Apolipoprotein C-III, Hyperlipoproteinemia Type I, Oligonucleotides, Antisense, RNA, Messenger, Liver, RNA, Small Interfering, Triglycerides, Animals, Oligonucleotides, Treatment Outcome, Genetic Therapy, Antisense oligonucleotide, Familial chylomicronemia syndrome, Hepatic targeting therapies, Hypertriglyceridemia, RNA therapies, Small interfering RNA
Published Open-Access
yes
Recommended Citation
Brinton, Eliot A; Eckel, Robert H; Gaudet, Daniel; et al., "Familial Chylomicronemia Syndrome and Treatments To Target Hepatic APOC3 mRNA" (2025). Faculty, Staff and Students Publications. 6659.
https://digitalcommons.library.tmc.edu/baylor_docs/6659